5-fluorodopa has been researched along with Huntington Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashworth, S; Bloomfield, PM; Fricker, RA; Hume, SP; Jones, T; Lammertsma, AA; Myers, R; Rajeswaran, S; Torres, EM; Watson, I | 1 |
| Martin, WR | 1 |
1 review(s) available for 5-fluorodopa and Huntington Disease
| Article | Year |
|---|---|
Positron emission tomography in movement disorders.
Topics: Brain; Cerebrovascular Circulation; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dystonia; Glucose; Humans; Huntington Disease; Levodopa; Movement Disorders; Oxygen Consumption; Parkinson Disease; Synapses; Tomography, Emission-Computed | 1985 |
1 other study(ies) available for 5-fluorodopa and Huntington Disease
| Article | Year |
|---|---|
The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease.
Topics: Animals; Carbidopa; Carbon Isotopes; Carrier Proteins; Cerebellum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Huntington Disease; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Tomography, Emission-Computed | 1996 |